TREATMENT OF INFANTILE FACE HEMANGIOMAS WITH PROPRANOLOL

Abstract

The aim of the study was to increase the effectiveness of treatment of facial hemangiomas in children because of the usage of non-selective beta-blocker - propranolol in complex treatment. Materials and methods of research. 18 children under the age of 1 year with maxillofacial hemangiomas were observed. Localized hemangioma was observed in 38.8% (n=7). In 44.4% (n=8) hemangiomas occupied 2-3 adjacent anatomical areas. In 16.8% (n=3) hemangioma occupied more than 3 anatomical areas. For drug therapy of facial hemangiomas in children, non-selective beta - blockers - «Propranolol»were used. Results. The minimum course of treatment was 6 months, the average - 9 months, the maximum - 13. Treatment was completed in 11 (61.1%) children, 4 of them (22.2%) had involution of education. 2 (11.1%) were operated after a course of therapy of betablockers. 5 (27.8%), after 12 months of photothermolysis. Another 5 (27.8%) continue to receive drug therapy with non-selective beta-blockers to date. there is a positive dynamics, consisting in persistent degradation of tumor volume. All children had a significan t decrease in the area and volume of hemangioma. Summary. Localization of vascular tumors in the maxillofacial region, rapid growth, leading to irreversible functional and aestheti c disorders - is a direct indication for active therapy. Treatment of facial hemangiomas in children with non-selective beta-blockers as an independent method refers to the method of choice, in case of impossibility or high risk of surgical treatment, or is part of the combined treatment.